Company news

Imugene Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Imugene Oncolytic Virus Presentation at AACR 2021 Meeting

April 11, 2021

Final Highest Dose in Phase 1 Clinical Trial of PD-VAXX

April 6, 2021

S&P DJI Announces March 2021 Quarterly Rebalance

March 12, 2021

Imugene to Present HER-Vaxx Phase 2 Data at AACR21 Meeting

March 10, 2021

Imugene Commences Cohort 2 Dosing in Phase 1 PD1-VAXX Trial

February 11, 2021

Imugene Dose Escalates in PD1-VAXX Phase 1 Clinical Trial

January 20, 2021

Imugene completes recruitment to her-vaxx phase 2 trialim

January 6, 2021

Imugene Enrols First Cohort of PD1-Vaxx Clinical Trial

December 16, 2020

Imugene Receives $4.82 million R&D Tax Incentive

December 10, 2020

Imugene First Patient Dosed in PD1-VAXX Clinical Trial

November 30, 2020

Imugene HER Vaxx shows positive Overall Survival in trial

November 22, 2020

Imugene Receives FDA IND Approval for PD1-VAXX Trial in USA

November 1, 2020

Imugene Immunotherapy Combination Patent Granted in US

October 1, 2020

Imugene Secures $5.7 million Option Underwriting Agreement

September 8, 2020

Imugene Receives PD1-VAXX Ethics Trial Approval in USA

September 3, 2020

Appendix 4E & Annual Report to shareholders

August 31, 2020

Imugene Receives Third PD1-VAXX Ethics Trial Approval

August 20, 2020

Imugene Receives Clinical Guidance from US FDA for Vaxinia

August 5, 2020

Imugene Receives Second PD1-VAXX Ethics Trial Approval

July 16, 2020

Imugene Receives Ethics Approval to Start PD1-VAXX Trial

July 13, 2020

Imugene HER-Vaxx Phase 2 Clinical Update

May 3, 2020

Imugene PD1-Vaxx Immunotherapy Update

January 27, 2020

Imugene HER-Vaxx Immunotherapy Patent Granted in US

January 13, 2020

Imugene Share Placement to raise $24.6 million

December 1, 2019

Imugene Receives $4.13 million R&D Tax Incentive

November 4, 2019

US Defense Grant to Study Imugene CF33 Oncolytic Virotherapy

October 22, 2019

CF33 Oncolytic Virus Clinical Trial Program Update

October 20, 2019

Comprehensive Phase Ib HER-Vaxx Results Presented at ESMO

September 30, 2019

Investor Presentation - Proposed Acquisition

July 14, 2019

New HER-Vaxx Cancer Vaccine trial data presented at ESMO GI

July 7, 2019

Appendix 4C - Quarterly and Business Update

April 15, 2019

IMU presents new mimotope PD-1 vaccine data at AACR

April 2, 2019

IMU presents new KEY-Vaxx and B-Vaxx data at AACR

April 1, 2019

IMU Pre-IND FDA Meeting Provides Guidance for KEY-Vaxx

March 19, 2019

Imugene doses first patient in HER-Vaxx phase 2 trial

March 13, 2019

IMU Announces Presentations on KEY-Vaxx and B-Vaxx at AACR

March 3, 2019

Pause in Trading

February 27, 2019

IMU Meets Endpoints in Phase 1b Gastric Cancer Trial

December 16, 2018

Imugene Advances to Phase 2 in Gastric Cancer Trial

November 12, 2018

Imugene Receives $1.85 million R&D Tax Incentive

November 8, 2018

Imugene commences cGMP manufacture of PD-1 cancer vaccine

September 20, 2018

Imugene Completes Phase 1b Cancer Vaccine Trial Recruitment

September 10, 2018

Appendix 4E and Audited Financial Report

August 31, 2018

PD-1 cancer vaccine development update

July 22, 2018

Imugene raises $20.1 million

June 7, 2018

Imugene Licences Extensive B-Cell Immuno-Oncology Portfolio

June 6, 2018

Leslie Chong Appointed as Managing Director

March 27, 2018

Arginine Modulator Active in Cancer Models

February 18, 2018

Novel Anti-PD-1 Mimotope Vaccine Ready for Development

February 11, 2018

IMU Meets Investigator for Gastric Cancer Clinical Trial

February 8, 2018

← Newer news releases · Older news releases →

Decks

The 5 newest of 46 decks. Every deck is listed under its year.